Ionis Pharmaceuticals (IONS) Invested Capital (2009 - 2026)

Ionis Pharmaceuticals' Invested Capital history runs 18 years deep, the most recent figure standing at $923.9 million for Q1 2026.

• In Q1 2026, Invested Capital rose 94.21% year-over-year to $923.9 million; the TTM figure through Mar 2026 stood at $923.9 million (up 94.21% YoY), while the FY2025 annual figure was $921.0 million, up 56.55% from the prior year.
• Invested Capital was $923.9 million for Q1 2026 at Ionis Pharmaceuticals, roughly flat from $921.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $1.3 billion in Q2 2025 to a low of $308.1 million in Q2 2024.
• Historically, Invested Capital has averaged $644.3 million across 5 years, with a median of $588.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Invested Capital plunged 47.36% in 2023, then surged 309.53% in 2025.
• A 5-year view of Invested Capital shows it stood at $572.9 million in 2022, then dropped by 24.76% to $431.0 million in 2023, then jumped by 36.5% to $588.4 million in 2024, then soared by 56.55% to $921.0 million in 2025, then climbed by 0.31% to $923.9 million in 2026.
• The last three Invested Capital figures came in at $923.9 million (Q1 2026), $921.0 million (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.